不同化疗方案治疗成人初治非M3型AML的完全缓解率及不良反应

Complete Remission Rate and Adverse Ractions of Three Different Chemotherapy Regimens in the Treatment of Adult Patients with Newly Diagnosed Non-M3 AML

目的:比较3种不同化疗方案(柔红霉素、国产去甲氧柔红霉素、进口去甲氧柔红霉素分别联合阿糖胞苷)治疗成人初治非M3型急性髓系白血病(AML)的完全缓解率及不良反应。方法:将本院收治的71例成人初治非M3型AM L患者按治疗方案分为3组:A组:应用柔红霉素+阿糖胞苷方案(17例);B组:应用国产去甲氧柔红霉素+阿糖胞苷方案(24例);C组:应用进口去甲氧柔红霉素+阿糖胞苷方案(30例)。比较3组患者治疗后的疗效及不良反应的发生情况。结果:C组完全缓解率(86.67%)显著高于A组(52.94%)和B组(70.83%),B组完全缓解率显著高于A组(P<0.05)。3组患者出现恶心呕吐、感染和骨髓抑制等不良反应发生率无统计学差异(P>0.05)。结论:去甲氧柔红霉素对非M3型AM L患者的疗效优于柔红霉素,尤其进口药物的临床疗效更高;柔红霉素与去甲氧柔红霉素治疗后发生不良反应均在可控范围,故二者均可作为治疗AML患者的一线药物,患者可根据自身经济能力选择更为合适的药物。

Objective： To compare the complete remission rate （CRR） and adverse reaction of the 3 different chemotherapy regimens （dannorubicin, idarubicin, imported idarubicin combined with cytarabine） for the treatment of adult patients with newly diagnosed non - M3 acute myeloid leukemia （AML）. Methods ： Seventy - one adult patients with newly diagnosed non -M3 AML were divided into 3 groups： 17 cases treated with dannorubicin plus cytarabine as group A, 24 cases treated with idarubicin plus cytarabine as group B, 30 cases treated with the imported idarubicin plus cytarabine as group C. The curative effects and adverse reactions were compared among the 3 groups after treatment. Results：CCR in group C （86. 67% ） was significantly higher than that in group A （52.94%） and group B （70. 83% ）, and the CRR in group B was significantly higher than that in group A （ P 〈 0. 05 ）. The incidence of adverse reaction such as nausea, vomiting, myelosuppression and infection among 3 groups were not statistically significantant （P 〉 0. 05 ）. Conclusion ： The curative effect of idarubicin for the treatment of non - M3 AML patients is better than that of daunorubicin, especially the curative efficiency of imported darubicin is much higher; the adverse reaction after treatment by dannorubicin and idarubicin can be controllable, so daunorubicin and idarubicin can be used as first - line drug for the patients with AML, and patients can choose more appropriate drug according to their own economic ability.